ALG11

Across TCGA pan-cancer cohorts, ALG11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ALG11 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ALG11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ALG11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where ALG11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.869	0.629	.004	41	view →
PDAC	OS	Median	II,III,IV	0.632	0.367	.005	21	view →
LSCC	DFS	Tertile	II,III,IV	0.790	1.000	.015	14	view →
HNSC	DFS	Median	All	0.698	1.000	.020	9	view →
OV	DFS	Median	All	0.862	1.000	.037	4	view →
LUAD	DFS	Median	III,IV	0.683	0.324	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ALG11–CCRCC (DFS)

Open the CCRCC breakdown →